RHACE 1: Rapid HepAtitis C Elimination Trial - A Pilot Evaluation of Twice Daily Fixed Dose Combination Asunaprevir +Daclatasvir + BMS-791325 +- Weight Based Ribavirin in Treatment-Naive, Non-cirrhotic Patients With Chronic Genotype 1a Hepatitis-C for Eight, Six or Four Weeks
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2016
Price : $35 *
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms RHACE-1
- 15 Apr 2016 Status changed from recruiting to completed.
- 17 Nov 2015 Interim results (n=12) presented at The Liver Meeting 2015: 66th Annual Meeting of the American Association for the Study of Liver Diseases.
- 11 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.